ENZN · Enzon Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19M | - | - | - | - | - | - | $26.0K | $0 | - |
| Cost of Revenue | $79.78M | - | - | - | - | - | - | - | - | - |
| Gross Profit | $14.41M | - | - | - | - | - | - | - | - | - |
| R&D | $558.0K | - | - | - | - | - | - | - | - | - |
| SG&A | $11.70M | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | $1.30M | $1.53M | $1.00M | - | $351.0K | $351.0K | $326.0K | - |
| D&A | $5.38M | - | - | - | - | - | - | - | - | - |
| Operating Income | ($4.33M) | - | ($1.30M) | ($1.53M) | ($1.00M) | - | ($351.0K) | ($325.0K) | ($326.0K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $748.0K | - | $16.0K | ($42.0K) | $19.0K | - | $49.0K | $4.0K | $1.0K | - |
| Net Income | ($6.69M) | - | ($824.0K) | ($990.0K) | ($524.0K) | - | $254.0K | $276.0K | $320.0K | - |
| EPS - Basic | ($0.84) | - | ($0.02) | ($0.02) | ($0.01) | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | ($0.84) | - | ($0.02) | ($0.02) | ($0.01) | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.62M | $42.57M | $43.26M | $44.29M | $44.97M | $46.86M | $46.63M | $46.23M | $45.99M | $47.01M |
| Accounts Receivable | $60.18M | - | - | - | - | - | - | - | - | - |
| Inventory | $96.75M | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $36.89M | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K | $331.0K |
| Current Assets | $234.58M | $42.81M | $43.67M | $44.74M | $45.52M | $47.15M | $46.97M | $46.64M | $46.47M | $47.34M |
| Total Assets | $428.87M | $42.81M | $43.69M | $44.78M | $45.52M | $47.17M | $47.28M | $46.99M | $46.83M | $47.70M |
| Current Liabilities | $116.94M | $731.0K | $540.0K | $803.0K | $554.0K | $1.68M | $438.0K | $410.0K | $521.0K | $1.71M |
| Long-term Debt | $79.73M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $192.20M | ($2.52M) | ($923.0K) | $432.0K | $1.95M | $3.01M | $2.76M | $3.04M | $3.29M | $3.50M |
| Retained Earnings | ($18.57M) | ($73.30M) | ($72.23M) | ($71.41M) | ($70.42M) | ($69.89M) | ($69.82M) | ($70.07M) | ($70.35M) | ($70.67M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.32M) | - | - | - | ($618.0K) | - | - | - | $251.0K | - |
| Investing Cash Flow | ($8.98M) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $44.75M | - | - | - | ($1.27M) | - | - | - | ($1.27M) | - |
| CapEx | $7.35M | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($23.67M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 15.3% | - | - | - | - | - | - | - | - | - |
| Operating margin | -4.6% | - | - | - | - | - | - | -1250.0% | - | - |
| EBITDA margin | 1.1% | - | - | - | - | - | - | - | - | - |
| Net margin | -7.1% | - | - | - | - | - | - | 1061.5% | - | - |
| Free cash flow margin | -25.1% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 3.54 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 0.6% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 12.4% | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | 16.2% | 1.4% | 0.3% | - |
| Return on assets | -1.6% | - | -1.9% | -2.2% | -1.2% | - | 0.5% | 0.6% | 0.7% | - |
| Return on equity | -3.5% | - | 89.3% | -229.2% | -26.8% | - | 9.2% | 9.1% | 9.7% | - |
| Return on invested capital | -1.3% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.01 | 58.57 | 80.86 | 55.71 | 82.17 | 28.10 | 107.24 | 113.75 | 89.19 | 27.62 |
| Quick ratio | 1.18 | 58.57 | 80.86 | 55.71 | 82.17 | 28.10 | 107.24 | 113.75 | 89.19 | 27.62 |
| Cash ratio | 0.24 | 58.24 | 80.10 | 55.16 | 81.17 | 27.93 | 106.47 | 112.75 | 88.27 | 27.43 |
| Leverage | ||||||||||
| Debt / Equity | 0.41 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.19 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | 76.15 | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.23 | -16.96 | -47.34 | 103.66 | 23.31 | 15.68 | 17.12 | 15.46 | 14.22 | 13.61 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.22 | - | - | - | - | - | - | 0.00 | 0.00 | - |
| Inventory turnover | 0.82 | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 233d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 443d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 169d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | 507d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.3x | - | - | 22.3x | 3.8x | - | 3.8x | 4.4x | 2.0x | - |
| P / S | 0.6x | - | - | - | - | - | - | 513.8x | - | - |
| EV / EBITDA | 103.7x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -55.3% | - | - |
| Revenue CAGR (5y) | 201.0% | - | - | - | - | - | - | -34.0% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -332.4% | - | -271.5% | -371.7% | -207.4% | - | -56.0% | -2.2% | -14.4% | - |
| Net income growth (YoY) | -1176.5% | - | - | - | - | - | -20.9% | 50.8% | 62.4% | - |
| EPS growth (YoY) | -8300.0% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 9741.3% | - | - | -85.8% | -40.7% | -14.2% | 9.8% | 11.5% | 7.2% | 2.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$22.0K totalRoyalty$22.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ENZON PHARMACEUTICALS against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 30, 2019 | $0.1200 |
| Feb 20, 2019 | $0.0600 |
| Sep 29, 2017 | $0.1500 |
| Dec 13, 2016 | $0.1500 |
| Dec 30, 2015 | $0.2500 |
| Aug 13, 2015 | $0.5000 |
| Jan 8, 2015 | $0.1000 |
| Dec 24, 2013 | $0.4500 |
| Jun 5, 2013 | $1.6000 |
| Dec 6, 2012 | $2.0000 |